Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12560649 | 0.84 | BRD4 (0.46) | LMNATDP1PTGDR2G6PDIDE | |
| SCHEMBL29093586 | 0.83 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNATDP1SMN1; SMN2 | |
| SCHEMBL1940207 | 0.81 | LMNA (0.38) | LMNATDP1PTGDR2G6PDIDE | |
| SCHEMBL15486517 | 0.81 | LOX (0.44) | LMNATDP1PTGDR2G6PDIDE | |
| SCHEMBL710400 | 0.81 | PTGDR2 (0.43) | LMNATDP1PTGDR2G6PDIDE | |
| SCHEMBL8018423 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNAPTGDR2PTGS2 | |
| SCHEMBL16434137 | 0.79 | PTGS2 (0.45) | ALDH1A1MAPTLMNAPTGDR2SMN1; SMN2 | |
| SCHEMBL30721131 | 0.79 | PTGS2 (0.45) | ALDH1A1MAPTLMNAPTGDR2SMN1; SMN2 | |
| SCHEMBL12226960 | 0.78 | ENPP2 (0.39) | LMNAPTGDR2BRD4PTGS2ENPP2 | |
| SCHEMBL25735735 | 0.78 | SMN1; SMN2 (0.43) | ALDH1A1MAPTLMNATDP1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| CN-102216249-A | Naphthylacetic acids | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | ALDH1A1 754/4885MAPT 4559/4885LMNA 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.